|

EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

RECRUITINGN/ASponsored by University Hospital, Clermont-Ferrand
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Clermont-Ferrand
Started2018-02-01
Est. completion2025-05-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03481868

Summary

Primary objective : To identify epigenetic dysregulations of in vivo TKI-resisting CML cells Hypothesis : An epigenetic dysregulation is involved in the in vivo survival of a CML cell subclone despite the use of TKIs

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patient newly diagnosed for Chronic Myeloid Leukemia in chronic phase
* Patient older than 18 years old
* Patient who received no treatment for CML at the time of sampling on D0
* Intention of prescription with first-line treatment with TKI only
* Choice of first-line CML treatment by TKI only
* Patient having signed an informed consent
* Patient with a social security system

Exclusion Criteria:

* Contra-indication to the use of TKI
* Probability of poor compliance during treatment
* Patients already treated for CML

Conditions3

CancerChronic Myeloid Leukemia (CML)Chronic Phase

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.